

CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

PROPOSED PLACEMENT OF:

- (A) UP TO 990,000,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT AN ISSUE PRICE OF S\$0.002 PER PLACEMENT SHARE; AND
 - (B) UP TO 660,000,000 FREE WARRANTS, ON THE BASIS OF TWO (2) WARRANTS FOR EVERY THREE (3) PLACEMENT SHARES, WITH EACH WARRANT CARRYING THE RIGHT TO SUBSCRIBE FOR ONE (1) NEW ORDINARY SHARE IN THE CAPITAL OF THE COMPANY.
- COMPLETION OF THE PROPOSED PLACEMENT CUM WARRANT ISSUE
-

The board of directors (the “**Board**”) of Clearbridge Health Limited (the “**Company**”) refers to the announcements of the Company dated 4 August 2025 and 13 August 2025 (the “**Placement Announcements**”) in relation to the Proposed Placement cum Warrant Issue. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Placement Announcements.

The Board is pleased to announce that the Company has completed the Proposed Placement cum Warrant Issue, and that 990,000,000 Placement Shares and 659,999,996 Warrants were issued to the placees in accordance with the terms of the Placement Agreement.

Following the completion of the Proposed Placement cum Warrant Issue, the total number of issued Shares of the Company has increased from 3,305,820,825 Shares to 4,295,820,825 Shares.

The Placement Shares rank in all respects *pari passu* with the then existing issued Shares, except that they will not rank for any dividends, rights, allotments or other distributions, the record date of which falls on or before the date of issue of the Placement Shares.

The Placement Shares are expected to be listed and quoted on the Catalist Board of the SGX-ST on or around 20 August 2025.

By Order of the Board

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

18 August 2025

*This announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited (the “**Sponsor**”).*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.